ACEI superior to ARB in diabetes

ACE inhibitors (ACEI) come up trumps over angiotensin receptor blockers (ARBs) for patients with type 2 diabetes, a meta-analysis suggests.

Challenging the tenet that there is little difference between the two drug classes, researchers found ACEIs reduced all-cause mortality by 13% and cardiovascular mortality by 17% compared with placebo or control drugs.

ARBs, by contrast, did not significantly reduce mortality compared to control medications, Chinese researchers wrote last week in JAMA Internal